How emotive supports companies launching advanced therapies

We are dedicated to advanced therapies & innovative treatments

At emotive, our simple vision is to change lives by helping those who are unwell to receive new and amazing treatments that can make them better. We offer an individual approach for companies developing advanced therapies and other innovative treatments for rare disorders to help them stimulate advocacy, uptake and access.

We are experienced in rare diseases

With 75% of our work dedicated to rare and ultra-rare disorders, many with orphan indications, we know rare disorders have their own unique complexities and challenges. This has given us a wealth of experience, supporting clients across a wide range of disorders and indications at all stages of the product lifecycle.

We are currently working in advanced therapies

We are currently working with several clients with advanced therapeutics, such as gene therapies, gene silencing and cell therapies. We are supporting these clients at a global level to create enhanced communication strategies, messages and tactics to achieve engagement with HCPs and other key stakeholders in the care pathway.

Over the last 3 years, We have supported the launch of two advanced therapies at a global level, and currently supporting the launch of an additional two. Our work with our client spans various activities, including:

• Created suites of MSL materials to reinforce a consistent narrative around a rare disorder and gene therapy treatment
• Developed and ran global symposia for clients to help raise awareness of rare disorders
• Built an internal eLearning programme to educate field teams on the disease area, cell therapy treatment, competitive landscape and latest clinical trial data
• Developed an insight-driven, targeted disease awareness campaign delivered to specialist HCPs, GPs and patients to support the launch of a gene-silencing treatment
• Facilitated expert forums and a screening strategy workshop with KOLs to understand the challenge and unmet needs in a disease area and helped them agree on the best practice for identifying patients suspected of having rare disorders

We have in-house experts in ATMP communications

At emotive, we have 10+ years of scientific and management experience in cell and gene therapies with an international network of ATMP scientists and medical professionals. Our experts also bring connections with academia as well as companies underpinning ATMP manufacturing and academia. With access to the wider emotive team and the consultancies within Synaptiq Health, clients are able to leverage highly skilled colleagues, including pharmacists, researchers and academics with scientific, medical, commercial, market access and creative expertise.

emotive is an independent, London-based, award-winning healthcare communications agency committed to changing lives by helping global life science companies bring novel and innovative products to patients. We recognise that only true engagement can facilitate change, and we use our combination of scientific, creative and technical expertise to stimulate optimal participation of all those in the care pathway. We are proud to work with amazing clients on some of the most exciting and meaningful products that will transform healthcare.    

If you would like to find out more about joining emotive, please contact jade.nuttaman@emotiveagency.com. For more information on our services, contact chat@emotiveagency.com